Trimel to Report Second Quarter 2013 Results and Host Investor Call
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 07/25/13 -- Trimel Pharmaceuticals Corporation (TSX: TRL) will report its second quarter financial results for the period ended June 30, 2013 on Wednesday, July 31, 2013 after the market closes.
Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Thursday, August 1, 2013, at 8:30 a.m. Eastern Daylight Time.
To access the call live, please dial 416-340-2216 (Toronto), 1-866-226-1792 (Canada and U.S.) or 00-800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.
A replay of the conference call will be available until 7:00 p.m. Eastern Daylight Time on Thursday, August 8, 2013 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 3086288#.
For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at .
About Trimel
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. A New Drug Application for CompleoTRT™, a product using Trimel's licensed bioadhesive intranasal technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit
Contacts:
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
416 679 0536
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.07.2013 - 15:00 Uhr
Sprache: Deutsch
News-ID 1249013
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
TORONTO, ONTARIO
Phone:
Kategorie:
Healthcare
Anmerkungen:
Diese Pressemitteilung wurde bisher 103 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Trimel to Report Second Quarter 2013 Results and Host Investor Call
"
steht unter der journalistisch-redaktionellen Verantwortung von
Trimel Pharmaceuticals Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
